Brain radioligands - State of the art and new trends

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 2, 2001, Pages 139-152

  Halldin, C ^a   Gulyas B ^a   Langer, O ^a   Farde, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Brain; Carbon radioisotopes; Fluorine radioisotopes; Radiopharmaceuticals; Tomography, emission computed; Tomography, emission computed, single photon

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALTANSERIN; ALTROPANE; BRAIN MONOAMINE; BRAIN RECEPTOR; BROMINE 76; CARBON 11; CARFENTANIL; CLORGYLINE; CYCLOFOXY; DIPRENORPHINE; DOPAMINE TRANSPORTER; DOXEPIN; EPIDEPRIDE; FLUMAZENIL; FLUORINE 18; IODINE 123; ISOREMOXIPRIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXYGEN 15; RACLOPRIDE; RADIOISOTOPE; RADIOLIGAND; ROBALZOTAN; SEROTONIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINE TRANSPORT; BINDING AFFINITY; CONFERENCE PAPER; DRUG BINDING SITE; DRUG CHOICE; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EVALUATION; EXPERIMENTAL ANIMAL; HUMAN; IMAGING; IN VIVO STUDY; ISOTOPE LABELING; MEDICAL RESEARCH; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; PATIENT; POSITRON EMISSION TOMOGRAPHY; PSYCHOPHARMACOLOGY; RADIOISOTOPE DECAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOLUNTEER;

ANIMALS; BRAIN; CARRIER PROTEINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034931817     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (150)

1. Positron emission tomography: Principles and quantitation
2. PET: The merging of biology and imaging into molecular imaging
3. The advantage of using positron emission tomography in drug research
4. PET and drug research and development
5. Emission tomography
6. PET instrumentation: What are the limits?
7. A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: The advantage of a longer half-life!
8. Radiotracers: Synthesis and use in imaging
9. Positron-emitting radioligands for studies in vivo - Probes for human psychopharmacology
10. Imaging of neurotransmitter receptors in the living human brain
11. PET evaluation of the dopamine system of the human brain
12. Dopamine receptor radioligands
13. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
14. Development of imaging agents for the dopamine transporter
15. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development
16. Non-invasive radiotracer imaging as a tool for drug development
17. Radioligands for the study of brain 5-HT1A receptors in vivo
18. Pharmacokinetic considerations in the PET and SPECT evaluation of CNS receptors
19. Imaging of the serotonergic system: Interactions of neuroanatomical and functional abnormalities of depression
20. Changes in apparent rates of receptor binding in the intact brain in relation to the heterogeneity of reaction environments
21. PET studies of brain monoamine transporters
22. Comparison of fluorine-18 and bromine-76 imaging in positron emission tomography
23. Alternative positron emission tomography with non-conventional positron emitters: Effects of their physical properties on image quality and potential clinical applications
24. 18F]fluoroarenes
25. Recommendations for fluorine-18 production
26. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules
27. No-carrier-added radiohalogenation methods with heavy halogens
28. Bromine radiopharmaceuticals: Radiopharmaceuticals labelled with bromine isotopes
29. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1
30. Radiotracers for PET studies of neurotransmitter binding sites: Design considerations
31. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
32. Radioligand disposition and metabolism. Key information in early drug development
33. Relationship between lipophilicity and brain extraction of C-11-labeled radio-pharmaceuticals
34. Effect of lipophilicity on the in vivo localization of radiolabelled spiperone analogues
35. 11C]WAY-100635 - Explanation of high signal contrast in PET and an aid to biomathematical modelling
36. Fluoro-norchloroepibatidine: Preclinical assessment of acute toxicity
37. 11C-raclopride and positron emission tomography
38. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
39. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies
40. Whole hemisphere autoradiography of the postmortem human brain
41. Human brain imaging postmortem - Whole hemisphere technologies
42. Chemical neuroanatomy and in vitro receptor autoradiography: A basis for cerebral positron emission tomography
43. 11C]MADAM - A selective radioligand for PET-examination of the serotonin transporter in the monkey brain
44. 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography
45. 11C-raclopride
46. Carbon-11-NNC 112: A radioligand for PET examination of striatal and neocortical D1-dopamine receptors
47. 11C]NNC 112 in humans: Validation and reproducibility
48. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding
49. Carbon-11 FLB 457: A radioligand for extrastriatal D2 dopamine receptors
50. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain
51. (3-N-(11C)methyl-spiperone, a ligand binding to dopamine receptors: Radiochemical synthesis and biodistribution studies in mice
52. Imaging dopamine receptors in the human brain by positron tomography
53. 18F-fallypride
54. 18F]fallypride in nonhuman primates
55. 18F]-fluoroethyl)-spiperone: A novel ligand for cerebral dopamine receptor studies with PET
56. 76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET
57. Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach
58. 123I]epidepride single-photon emission tomography
59. 123I]epidepride SPECT
60. 123I-IBZM single photon emission computerized tomography study
61. PET-characterization of [C-11]PE2I binding to dopamine receptors in the monkey brain
62. 11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET
63. 11C]β-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography
64. 11C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain
65. 11C]WIN 35,428
66. 127I]Altropane: A highly selective ligand for PET imaging of dopamine transporter sites
67. Mapping cocaine binding sites in human and baboon brain in vivo
68. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain
69. Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron
70. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate
71. 18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: Characterization in human subjects
72. 11C]β-CIT-FP for quantitation of the dopamine transporter
73. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)no rtropane and the first human study with positron emission tomography
74. 123I]-2β-carbomethoxy-3β(4-iodophenyl)-tropane: High-affinity SPECT radiotracer of monoamine reuptake sites in brain
75. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters on Parkinson disease
76. Exploration of the dopamine transporter: In vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative(E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′- methylphenyl)nortropane (PE2I)
77. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
78. 123I]N-ω-fluoroalkyl -2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons
79. Iodine-123 labeled N-(2-fluoroethyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
80. Comparison of iodine-123 labeled 2β-carbomethoxy-3β-(-4-iodophenyl)tropane (β-CIT) and 2β-carbomethoxy-3β-(-4-iodophenyl)-N-(3-fluoropropyl)nortropane (β-CIT-FP) for the dopamine transporters in the living human brain
81. Altropane, a SPECT or PET imaging probe for dopamine neurons. I. Dopamine transporter binding in primate brain
82. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging
83. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635
84. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man
85. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo
86. 1A receptor
87. 1A antagonists
88. 1A receptor antagonist, WAY-100635
89. 1A receptors with PET
90. 18F]p-MPPF
91. [11C]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography
92. 11C]MDL 100907
93. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain
94. Ligands and tracers for PET studies of the 5-HT system
95. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex
96. 18F-labelled setoperone
97. Radiosynthesis of a new radioiodinated ligand for serotonin 5HT2 receptors, a promising tracer for γ-emission tomography
98. 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects
99. 11C-labeled 2-(phenylthio) araalkylamines
100. 11C]DASB
101. Radioligand development for studying serotonin uptake sites with positron emission tomography
102. 11C](+)McN5652
103. In vitro and in vivo characterisation of nor-β-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain
104. PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter
105. 2-((2-(Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An improved serotonin transporter ligand
106. 123I]β-CIT: Pharmacological characterization of brain uptake in nonhuman primates
107. Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
108. 123I]ZIENT: A new high affinity and selective SERT imaging agent
109. 11C]carfentanil
110. 11C]carfentanil binding to opiate receptors in humans measured by positron emission tomography
111. Synthesis of ligands for imaging opiate receptors by positron emission tomography: Carbon-11 labeled diprenorphine
112. 11C]buprenorphine from 3-O-trityl protected precursors
113. 11C]diprenorphine PET study
114. 18F]cyclofoxy
115. Opiate receptor activity and cerebral blood flow in Alzheimer's disease
116. 11C): A specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography
117. 11C-Ro 15-1788 binding to the human neocortex using positron emission tomography
118. Radioligands for PET studies of central benzodiazepine receptors and PK binding sites - Current status
119. 11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography
120. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors
121. 123I-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding
122. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5- methyl-6-oxo-4H-imidazo(1,5a)-(1,4)-benzodiazepine (NNC 13-8241)
123. Synthesis of suicide inhibitors of monoamine oxidase Carbon-11 labelled clorgyline, L-deprenyl and D-deprenyl
124. 11C-labeled suicide inactivators and PET
125. Maintenance of brain monoamine oxidase B in smokers after overnight cigarette abstinence
126. Brain monoamine oxidase A inhibition in cigarette smokers
127. 11C]NMPB), a muscarinic acetylcholine receptor antagonist
128. 11C]NMPB and PET
129. 11C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography
130. 11C]4-MPB
131. 11C-methyl]benztropine
132. 11C]benzotropine in the human brain with graphic analysis and spectral analysis
133. Muscarinic acetylcholine receptors in Alzheimer's disease
134. SPECT imaging of central muscarinic acetylcholine receptors with iodine-123 labeled E-IQNP and Z-IQNP
135. 2-, 5-, and 6-halo-3-(2(S)-azetidinylmethoxy)pyridines: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling
136. 18F]fluoro-A-85380
137. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine: A new positron emission tomography ligand for nicotinic receptors
138. 18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors
139. 123I]5-I-A-85380
140. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[116]dihydrotetrabenzine (DTBZ) and positron emission tomography
141. 125-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol
142. In vivo mapping of cholonergic neurons in the human brain using SPECT and IBVM
143. 1 receptors in patients with Alzheimer's disease assessed by positron emission tomography
144. 1 receptors in the human brain using [11C]pyrilamine and positron emission tomography
145. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease
146. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease
147. 11C-labelled L-tyrosine and L-DOPA
148. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease
149. Dopamine visualized in the basal ganglia of living man